Bipolar disorder treatment market is anticipated to grow at a CAGR of 2.6% during the forecast period owing to the rising prevalence of bipolar disorder, along with the rising awareness about mental health. Other factors, such as increased government initiatives and increased demand for innovative treatment choices, are likely to boost market expansion. Additionally, advancements in technology have also played a significant role in the growth of the bipolar disorder treatment market. Digital health tools, such as telemedicine and online counselling platforms, have made bipolar illness treatment more accessible to patients who may have difficulty accessing traditional in-person care. This has increased the accessibility of bipolar illness treatment and helped to fulfil the rising demand for treatments.

Segmental Outlook  

The global bipolar disorder treatment market is segmented based on the drug class and distribution channel. Based on the drug class, the market is sub-segmented into mood stabilizer, anticonvulsant, antipsychotic drug, antidepressant drug, other. Based on, distribution channel, the market is sub-segmented into on hospitals and clinics, retail pharmacies, and online pharmacies. Among the distribution channel, the hospitals and clinics sub-segment is anticipated to hold a considerable share of the market as clinics or hospitals are primary provider of bipolar disorder treatment. Additionally, presence of large number of hospitals or clinics as compared to retail pharmacies is driving the growth of this segment.

Antipsychotic Drug Sub-Segment is Anticipated to Hold a Prominent Share in the Global Bipolar Disorder treatment Market

Among the drug class, antipsychotic drug is anticipated to hold a prominent share of the market. Antipsychotic medicines are used in the short term to manage psychotic symptoms of bipolar illness, such as hallucinations, delusions, or manic symptoms. These symptoms can emerge as a result of severe depression or extreme mania. Some additionally treat bipolar depression to avoid future bouts of mania or despair. The National Institute of Mental Health predicts approximately 2.8% of individuals in the United States have bipolar illness, according to an article titled "Medications for bipolar disorder: What you should know" released in May 2022. Aripiprazole, Cariprazine, Lurasidone, Olanzapine, and other 2nd-generation antipsychotics are increasingly being used to treat acute manic psychosis. Although any of these medicines may produce akathisia due to extrapyramidal side effects, the risk is reduced with more sedating drugs such as olanzapine and quetiapine. Antipsychotics are also used "off labels" as narcotics for a sleeping difficulty, stress, or probable disruption in people with bipolar illness. They are frequently used with a temperament balancing medicine and help reduce the negative effects of mania until mood stabilizers provide complete benefits. A few antipsychotics appear to help with relaxing states of mind all along. As a result, they might be used as a stand-alone therapy for those who can’t tolerate or respond to lithium and anticonvulsants.

Regional Outlook

The global bipolar disorder treatment market is further segmented based on geography including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, the European regional market is expected to grow considerably over the forecast period owing to factors such as the increasing awareness of mental health issue coupled with and government initiatives. Additionally, the region has established healthcare system, which supports the delivery of bipolar disorder treatment.

Global Bipolar Disorder Treatment Market Growth, by Region 2023-2030

North America is Expected to Hold a Prominent Share in the Global Bipolar disorder treatment

North America is dominating the bipolar disorder treatment market over the forecast period and expected to show a similar trend over the forecast period. The major factors propelling market growth include the rising prevalence of bipolar disorders due to insufficient sleep, trend of substance abuse, and high-stress levels amongst the population. Additionally, government initiatives aimed at raising awareness and support for patients suffering from mental disorder are expected to boost the market growth in the region. For instance, the Department of Health and Human Services (HHS), through the Substance Abuse and Mental Health Services Administration (SAMHSA), and the Office of Minority Health (OMH) funded $35 million to strengthen and expand community behavioural & mental health services including software for America's children and young adults in 2022. Such initiative is expected to enhance market expansion during the forecast period. Furthermore, the presence of modern healthcare infrastructure, together with rising healthcare expenditure, will contribute to market expansion. According to the National Alliance on Mental Illness, approximately 1 in every 5 adults in the US suffers from mental illness in any given year. Severe periods of mania and depression require hospitalisation to prevent individuals from hurting themselves or others.

Burden of Disease from Each Category of Mental Illness, US, 2019

Estimated Number of Disability-Adjusted Life Years (DALYs) per 100,000 people by mental illness.

Source- Institute for Health Metrics and Evaluation

Market Players Outlook

The major companies serving the global bipolar disorder treatment market include AbbVie Inc., Pfizer Inc., AstraZeneca, BrainsWay, Ltd., GlaxoSmithKline Plc, Janssen Pharmaceuticals Inc., Allergan PLC, Eli Lilly and Company, GlaxoSmithKline Plcand others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in July 2021, Alembic Pharmaceuticals received approval from US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) Desipramine Hydrochloride tablets USP in the strength of 10 mg, 25 mg, 50 mg, 75 mg, 100 mg, and 150 mg. Desipramine Hydrochloride tablets is used in the treatment of depression. The approved product is therapeutically equivalent to the reference listed drug product Norpramin tablets of Validus Pharmaceuticals LLC. 

The Report Covers

• Market value data analysis of 2022 and forecast to 2030.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global bipolar disorder treatment market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.